New cocktail aims to tame Hard-to-Treat lymphoma
NCT ID NCT06824701
First seen Jan 04, 2026 · Last updated May 25, 2026 · Updated 25 times
Summary
This early-phase trial tests whether adding the drug tazemetostat to two standard lymphoma drugs (zanubrutinib and an anti-CD20 antibody) is safe and works for people with indolent B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. About 24 adults with certain lymphoma types will take part. The main goal is to find the safest dose and see how many patients respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute at University of Uta
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.